Search research articles
Contact Us
Filters
Showing results (211-220 of 347) with videos related to
Page
of 35
Sort By:
Scientific Reports
|
November 27, 2025
Links between nocturnal hypoxia and cognitive function in breast cancer
Clara Elia, Joy Perrier, Mylène Duivon, et al.
Cancer
|
September 30, 2020
Cognitive rehabilitation program to improve cognition of cancer patients treated with chemotherapy: A 3-arm randomized trial
Mélanie Dos Santos, Isabelle Hardy-Léger, Olivier Rigal, et al.
BJU International
|
November 5, 2013
Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study
Florence Joly, Remy Delva, Loïc Mourey, et al.
Bulletin Du Cancer
|
March 29, 2023
[Endometrial stromal sarcoma: French Guidelines from the French Sarcoma Group and the Rare Malignant Gynecologic Tumors Group]
Coriolan Lebreton, Pierre Meeus, Catherine Genestie, et al.
Future Oncology (London, England)
|
May 5, 2025
DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients
François Cherifi, Isabelle Ray-Coquard, Maria Jesus Rubio, et al.
Breast Cancer Research : BCR
|
February 19, 2025
Interaction between APOE Ɛ4 status, chemotherapy and endocrine therapy on cognitive functioning among breast cancer survivors: the CANTO-Cog longitudinal study
Mylène Duivon, François Christy, Emilie Thomas, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 5, 2018
Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group
Emmanuel Meyer, David Pasquier, Guillemette Bernadou, et al.
Cancer
|
January 16, 2023
Baseline quality of life and chemotherapy toxicities in patients with early breast cancer
Idlir Licaj, Elodie Coquan, Tienhan Sandrine Dabakuyo-Yonli, et al.
European Urology
|
November 28, 2015
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial
Gwenaelle Gravis, Jean-Marie Boher, Florence Joly, et al.
Bulletin Du Cancer
|
September 15, 2022
[Practical management of PARP inhibitors: A French DELPHI consensus]
Frédéric Selle, Jean-Jacques Boffa, Gabriel Etienne, et al.
Page
of 35
Search research articles
Search
Showing results (211-220 of 347) with videos related to
Sort By:
Page
of 35
Scientific Reports
|
November 27, 2025
Links between nocturnal hypoxia and cognitive function in breast cancer
Clara Elia, Joy Perrier, Mylène Duivon, et al.
Cancer
|
September 30, 2020
Cognitive rehabilitation program to improve cognition of cancer patients treated with chemotherapy: A 3-arm randomized trial
Mélanie Dos Santos, Isabelle Hardy-Léger, Olivier Rigal, et al.
BJU International
|
November 5, 2013
Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study
Florence Joly, Remy Delva, Loïc Mourey, et al.
Bulletin Du Cancer
|
March 29, 2023
[Endometrial stromal sarcoma: French Guidelines from the French Sarcoma Group and the Rare Malignant Gynecologic Tumors Group]
Coriolan Lebreton, Pierre Meeus, Catherine Genestie, et al.
Future Oncology (London, England)
|
May 5, 2025
DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients
François Cherifi, Isabelle Ray-Coquard, Maria Jesus Rubio, et al.
Breast Cancer Research : BCR
|
February 19, 2025
Interaction between APOE Ɛ4 status, chemotherapy and endocrine therapy on cognitive functioning among breast cancer survivors: the CANTO-Cog longitudinal study
Mylène Duivon, François Christy, Emilie Thomas, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 5, 2018
Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group
Emmanuel Meyer, David Pasquier, Guillemette Bernadou, et al.
Cancer
|
January 16, 2023
Baseline quality of life and chemotherapy toxicities in patients with early breast cancer
Idlir Licaj, Elodie Coquan, Tienhan Sandrine Dabakuyo-Yonli, et al.
European Urology
|
November 28, 2015
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial
Gwenaelle Gravis, Jean-Marie Boher, Florence Joly, et al.
Bulletin Du Cancer
|
September 15, 2022
[Practical management of PARP inhibitors: A French DELPHI consensus]
Frédéric Selle, Jean-Jacques Boffa, Gabriel Etienne, et al.
Page
of 35